FibroBiologics, Inc. (FBLG) income statement
FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.84−0.06 (-6.72%)
Close on Nov 18, 2026Market cap $5.59MP/E –Yield –
FibroBiologics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -419.4%
Financial strength
- Current ratio
- 2.64
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 158.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.21
- Dividend yield
- –
See a number that looks wrong?